Table 1.
Demographics and disease characteristics
| Treatment sequence |
|||||||
|---|---|---|---|---|---|---|---|
| ABI-DOCE (n = 178) |
ABI-ENZA (n = 99) |
ABI-RAD (n = 27) |
DOCE-ABI (n = 191) |
DOCE-CABA (n = 74) |
DOCE-ENZA (n = 116) |
ENZA-DOCE (n = 42) |
|
| Age (yr) | |||||||
| Median | 74.0 | 78.0 | 74.0 | 69.0 | 68.5 | 71.0 | 70.5 |
| Range | (50–92) | (48–94) | (61–92) | (46–87) | (53–80) | (47–85) | (54–88) |
| Age group (yr), n (%) | |||||||
| <65 | 29 (16.3) | 10 (10.1) | 4 (14.8) | 57 (29.8) | 25 (33.8) | 26 (22.4) | 11 (26.2) |
| 65–74 | 69 (38.8) | 23 (23.2) | 10 (37.1) | 96 (50.3) | 35 (47.3) | 49 (42.3) | 18 (42.8) |
| ≥75 | 80 (44.9) | 66 (66.7) | 13 (48.1) | 38 (19.9) | 14 (18.9) | 41 (35.3) | 13 (31.0) |
| Gleason score at diagnosis, n (%) | |||||||
| N | 158 | 86 | 27 | 180 | 72 | 114 | 40 |
| ≤6 | 18 (11.4) | 16 (18.6) | 3 (11.1) | 26 (14.4) | 5 (6.9) | 7 (6.1) | 3 (7.5) |
| 7 | 63 (39.9) | 29 (33.7) | 8 (29.6) | 52 (28.9) | 23 (31.9) | 39 (34.2) | 13 (32.5) |
| 8–10 | 77 (48.7) | 41 (47.7) | 16 (59.3) | 102 (56.7) | 44 (61.1) | 68 (59.6) | 24 (60.0) |
| M stage at initial diagnosis, n (%) | |||||||
| N | 173 | 98 | 27 | 191 | 71 | 113 | 41 |
| Mx | 30 (17.3) | 17 (17.3) | 6 (22.2) | 34 (17.8) | 12 (16.9) | 16 (14.2) | 10 (24.4) |
| M0 | 68 (39.3) | 57 (58.2) | 11 (40.7) | 68 (35.6) | 24 (33.8) | 36 (31.9) | 16 (39.0) |
| M1, M1a, M1b, M1c | 75 (43.4) | 24 (24.5) | 10 (37.1) | 89 (46.6) | 35 (49.3) | 61 (53.9) | 15 (36.6) |
| Time from initial diagnosis of prostate cancer to first metastatic diagnosis (yr) | |||||||
| N | 175 | 95 | 26 | 181 | 71 | 113 | 42 |
| Median | 0.8 | 3.4 | 2.9 | 0.3 | 0.1 | 0.1 | 0.9 |
| Range | (0–24) | (0–21) | (0–16) | (0–17) | (0–11) | (0–15) | (0–19) |
| Presence of bone metastases, n (%) | |||||||
| N | 126 | 77 | 22 | 141 | 56 | 96 | 36 |
| Any | 83 (65.8) | 55 (71.5) | 17 (77.2) | 82 (58.2) | 38 (67.8) | 57 (59.4) | 19 (52.8) |
| ≥5 | 45 (35.7) | 29 (37.7) | 11 (50.0) | 52 (36.9) | 25 (44.6) | 34 (35.4) | 9 (25.0) |
| Present, number unknown | 28 (22.2) | 14 (18.2) | 5 (22.7) | 41 (29.1) | 16 (28.6) | 26 (27.1) | 9 (25.0) |
| Visceral metastases, n (%) | |||||||
| N | 145 | 81 | 23 | 169 | 66 | 95 | 34 |
| Liver only | 4 (2.8) | 4 (4.9) | – | 13 (7.7) | 7 (10.6) | 8 (8.4) | 2 (5.9) |
| Lung only | 9 (6.2) | 5 (6.2) | 1 (4.3) | 11 (6.5) | 5 (7.6) | 3 (3.2) | 1 (2.9) |
| Liver and lung | 1 (0.7) | 1 (1.2) | – | 3 (1.8) | 2 (3.0) | 2 (2.1) | – |
ABI = abiraterone acetate plus prednisone/prednisolone; CABA = cabazitaxel; DOCE = docetaxel; ENZA = enzalutamide; RAD = radium-223.